Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program
Abstract Clinical ascertainment and clinical outcome are key features of any large multisite study. In the ProNET and PRESCIENT research networks, the Accelerating Medicines Partnership® Schizophrenia (AMP®SCZ) Clinical Ascertainment and Outcome Measures Team aimed to establish a harmonized clinical...
Saved in:
Similar Items
-
Exploring the predictive value of structural covariance networks for the diagnosis of schizophrenia
by: Clara S. Vetter, et al.
Published: (2025-06-01) -
Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program
by: Johanna T. W. Wigman, et al.
Published: (2025-06-01) -
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample
by: Kelly Allott, et al.
Published: (2025-03-01) -
Computational modelling reveals neurobiological contributions to static and dynamic functional connectivity patterns
by: Linnea Hoheisel, et al.
Published: (2025-07-01) -
The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program
by: Michael P. Harms, et al.
Published: (2025-04-01)